Search research articles
Contact Us
Filters
Showing results (431-440 of 497) with videos related to
Page
of 50
Sort By:
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Cancer
|
December 13, 2017
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes
Fabio Efficace, Francesco Cottone, Gregory Abel, et al.
Cancer Medicine
|
January 28, 2023
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project
Giacomo Coltro, Emanuela Sant'Antonio, Giuseppe A Palumbo, et al.
Leukemia
|
September 22, 2012
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients
P Falco, F Cavallo, A Larocca, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
November 2, 2013
International Myeloma Working Group recommendations for global myeloma care
H Ludwig, J S Miguel, M A Dimopoulos, et al.
British Journal of Haematology
|
February 5, 2020
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Haifa Kathrin Al-Ali, Martin Griesshammer, Lynda Foltz, et al.
Annals of Hematology
|
March 13, 2024
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study
F Palandri, G Auteri, E Abruzzese, et al.
Hemasphere
|
March 25, 2025
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey
Claire N Harrison, David M Ross, Laura Maria Fogliatto, et al.
Cancers
|
May 13, 2023
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
Esther Natalie Oliva, Anna Candoni, Prassede Salutari, et al.
Page
of 50
Search research articles
Search
Showing results (431-440 of 497) with videos related to
Sort By:
Page
of 50
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Cancer
|
December 13, 2017
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes
Fabio Efficace, Francesco Cottone, Gregory Abel, et al.
Cancer Medicine
|
January 28, 2023
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project
Giacomo Coltro, Emanuela Sant'Antonio, Giuseppe A Palumbo, et al.
Leukemia
|
September 22, 2012
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients
P Falco, F Cavallo, A Larocca, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
November 2, 2013
International Myeloma Working Group recommendations for global myeloma care
H Ludwig, J S Miguel, M A Dimopoulos, et al.
British Journal of Haematology
|
February 5, 2020
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Haifa Kathrin Al-Ali, Martin Griesshammer, Lynda Foltz, et al.
Annals of Hematology
|
March 13, 2024
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study
F Palandri, G Auteri, E Abruzzese, et al.
Hemasphere
|
March 25, 2025
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey
Claire N Harrison, David M Ross, Laura Maria Fogliatto, et al.
Cancers
|
May 13, 2023
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
Esther Natalie Oliva, Anna Candoni, Prassede Salutari, et al.
Page
of 50